SCHEMBL4018016

SCHEMBL4018016

CC(CNS(=O)(=O)c1ccc(CN(Cc2cccc(Cl)c2)C(=O)C(=O)O)s1)c1ccc(Cl)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 3/20 0.37
LIMK2 P53671 3/20 0.36
LIMK1 P53667 2/20 0.36
CCKAR P32238 1/20 0.36
CCKBR P32239 1/20 0.36
SLC2A1 P11166 1/20 0.36
MDM2 Q00987 2/20 0.35
TP53 P04637 1/20 0.35
LMNA P02545 2/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TSHR P16473 1/20 0.34
RECQL P46063 1/20 0.34
PTGER4 P35408 3/20 0.34
PTGER2 P43116 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4017082 0.90 SERPINE1 (0.40) PTGESLMNAMEN1KMT2ANPSR1
SCHEMBL4017618 0.86 HTT (0.37) PTGESLMNAKMT2AHTT
SCHEMBL1857604 0.84 CASR (0.40) PTGESLIMK2LIMK1LMNAKDM4E
SCHEMBL4021417 0.83 LIMK2 (0.39) PTGESLIMK2LIMK1TP53LMNA
SCHEMBL4711948 0.82 CA1 (0.38) CCKARCCKBRMAPT
SCHEMBL1852104 0.82 KMT2A (0.50) LIMK2LIMK1TP53LMNAMEN1
SCHEMBL4020745 0.81 SMN1; SMN2 (0.48) LMNAALDH1A1KMT2AMAPTTSHR
SCHEMBL25737609 0.81 CNR1 (0.37) PTGESLIMK2LIMK1LMNAMEN1
SCHEMBL1854510 0.77 LPAR1 (0.45)
SCHEMBL4021244 0.76 HDAC4 (0.45) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US claimed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
EP-1986637-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS Laboratoires Serono SA (CH) 2008-11-05 EP disclosed
WO-2007093557-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS LABORATOIRES SERONO S.A. (CH) 2007-08-23 WO disclosed
WO-2007093557-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS LABORATOIRES SERONO S.A. (CH) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 PTGES 656/4885LIMK2 4230/4885LIMK1 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.